Complex genotype-phenotype relationships shape the response to treatment of down syndrome childhood acute lymphoblastic leukaemia
Year: 2025
Type: article
Study design: Observational Study
Abstract: Extensive genetic and epigenetic variegation has been demonstrated in many malignancies. Importantly, their interplay has the potential to contribute to disease progression and treatment resistance. To shed light on the complex relationships between these different sources of intra-tumour heterogeneity, we explored their relative contributions to the evolutionary dynamics of Acute Lymphoblastic Leukaemia (ALL) in children with Down syndrome, which has particularly poor prognosis. We quantified the tumour propagating potential of genetically distinct sub-clones using serial transplantation assays and SNP-arrays. While most leukaemias were characterized by a single dominant subclone, others were highly heterogeneous. Importantly, we provide clear and direct evidence that genotypes and phenotypes with functional relevance to leukemic progression and treatment resistance can co-segregate within the disease. Hence, individual genetic lesions can be restricted to well-defined cell immunophenotypes, corresponding to different stages of the leukemic differentiation hierarchy and varied proliferation potentials. As a result of this difference in fitness, which can be accurately quantified via competitive transplantation assays, matching diagnostic, post-treatment, and relapse leukaemias can be dominated by different genotypes, including pre-leukemic clones persisting throughout the disease progression and treatment. Intriguingly, plasticity also appears to be a temporally defined property that can segregate with genotype. These results suggest that Down Syndrome ALL should be viewed as a complex matrix of cells exhibiting genetic and epigenetic heterogeneity that foster extensive clonal evolution and competition. Therapeutic intervention reshapes this 'eco-system' and may provide the right conditions for the preferential expansion of selected compartments and subsequently relapse.
Source: Scientific Reports
Institutions: Heidelberg University, University College London, Lund University, John Radcliffe Hospital, University of Oxford, Karolinska Institutet, Universitätsklinikum Aachen, RWTH Aachen University, Skåne University Hospital, MRC Weatherall Institute of Molecular Medicine, German Cancer Research Center, DKFZ-ZMBH Alliance, Karolinska University Hospital
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,690
Funders: Leukemia and Lymphoma Society, NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, National Institute for Health and Care Research, Leukaemia and Lymphoma Research, Deutsche Forschungsgemeinschaft, Cancerfonden, Lunds Universitet, Barncancerfonden, Blood Cancer UK, Medical Research Council
OpenAlex ID: W4416724117
